MYC/BCL2-DH DLBCL are generally aggressive and respond poorly to currently available therapies, with the majority of patients dying within two years of diagnosis, although a minority of cases experience a long term survival [15, 16]. This evidence concerns the gene BCL2 and diffuse large B-cell lymphoma.